Publication date: Available online 22 February 2018
Source:Bioorganic & Medicinal Chemistry
Author(s): Shuangjie Shu, Antao Dai, Jiang Wang, Bin Wang, Yang Feng, Jia Li, Xiaoqing Cai, Dehua Yang, Dakota Ma, Ming-Wei Wang, Hong Liu
A novel series of 4-methyl substituted pyrazole derivatives were designed, synthesized and biologically evaluated as potent glucagon receptor (GCGR) antagonists. In this study, compounds 9q, 9r, 19d and 19e showed high GCGR binding (IC50 = 0.09 μM, 0.06 μM, 0.07 μM and 0.08 μM, respectively) and cyclic-adenosine monophosphate (cAMP) activities (IC50 = 0.22 μM, 0.26 μM, 0.44 μM and 0.46 μM, respectively) in cell-based assays. Most importantly, the docking experiment demonstrated that compound 9r formed extensive hydrophobic interactions with the receptor binding pocket, making it justifiable to further investigate the potential of becoming a GCGR antagonist.
Graphical abstract
http://ift.tt/2Fr7DK3
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου